Bispecific antibodies specifically binding to PD1 and LAG3
AssigneeHoffmnn-La Roche Inc.
InventorsLaura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
Life of this patent
Estimating the term…
Abstract
The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
Claims32
A method of treating an individual having a cancer comprising administering to the individual an effective amount of a bispecific antibody comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein
- said first antigen binding domain specifically binding to PD1 comprises a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3;
- and
- a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6, and
- the second antigen binding domain that specifically binds to LAG3 comprises
- (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 14, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:16;
- and
- a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 17, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19;
- or
- (b) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 22, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:23, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:24;
- and
- a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 25, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:27;
- or
- (c) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 30, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:31, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:32;
- and
- a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 33, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:34, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:35;
- or
- (d) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 38, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:40;
- and
- a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 41, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:43;
- or
- (e) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 46, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:48;
- and
- a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 49, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:50, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:51.
Dependencies are inferred from the claim text.